Creso Pharma delivers third order of Ritual Green brand
Creso Pharma Limited’s (ASX:CPH; FRA: 1X8) wholly-owned Canadian subsidiary, Mernova Medicinal Inc. a licensed producer in Nova Scotia, has received and successfully delivered its third purchase order (PO) from the Nova Scotia Liquor Corporation (NSLC).
The third PO is for 20 cases of Mernova’s ‘Mimosa’ (15-20% THC, less than 1% CBD) strain which is Mernova’s value brand now launched under the Ritual Green brand.
The introduction of the strain will allow Mernova to pursue a much larger addressable market, targeting consumers who are seeking premium quality at a more reasonable price-point.
This marks the third PO received from the NSLC in the last four weeks, with the two previous orders for the company’s premium strains, HPG13 (20-25% THC, < 1% CBD), and Lemon Haze (20-25% THC, < 1% CBD) continuing to sell well.
Creso is very confident that it will continue to receive purchase orders from the NSLC of its Mimosa and premium quality strains, allowing the company to build on the C$320,000 in revenue it has generated in the last month from the NSLC.
Mernova benefiting from e-commerce sales
Mernova’s Ritual Green products are sold through NSLC stores and e-commerce platform.
The additional purchase order serves as further confirmation of the success of the Ritual Green brand of high-quality cannabis products in the rapidly growing Canadian retail recreational market.
Mernova continues to make significant inroads into the Nova Scotia recreational market with its diverse products offering premium quality at a competitive price point.
Commenting on recent sales developments and the prospect of maintaining this momentum, Mernova managing director Jack Yu said, “Securing this additional purchase order from the NSLC is a significant achievement, and further validates the success of the recent Ritual Green product launch.
“Our products continue to garner very positive feedback from customers and we are confident that the Mimosa strain will unlock a large portion of the market that we can capitalise on in the near term.
“We look forward to updating shareholders on progress in Nova Scotia, additional strain launches under the Ritual Green product range, and further orders to be finalised in the near term.”
Latest articles on Creso Pharma
More Commentary
Creso Pharma’s vital competitive advantages key to the future
06-07-2021
BDA finishes fiscal 2021 on a high
01-07-2021
Why CPH investors should care about The HighBrid Lab
24-06-2021
Creso and Red Light Holland to merge into The HighBrid Lab
17-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.